Results 151 to 160 of about 73,039 (208)

Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. [PDF]

Clin Gastroenterol Hepatol
Ahuja D, Yeh KH, Patel SB, Lee HH, Goodwin SW, Solitano V, Ma C, Ananthakrishnan AN, Singh N, Jairath V, Xu R, Singh S.   +11 more
europepmc   +1 more source

Comparative analysis of hematological changes in patients with rheumatoid arthritis treated with different Janus kinase inhibitors: a real-world study. [PDF]

J Rheum Dis
Ahn SM, Oh JS, Kim YG, Lee CK, Yoo B, Hong S.   +5 more
europepmc   +1 more source

Complement and coagulation cascade cross-talk in endometriosis and the potential of Janus Kinase inhibitors-a network meta-analysis. [PDF]

Front Immunol
Golinska M, Rycerz A, Sobczak M, Chrzanowski J, Stawiski K, Fendler W.   +5 more
europepmc   +1 more source

Correction: Real‑World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis. [PDF]

Rheumatol Ther
Youssef P, Ciciriello S, Tahir T, Leadbetter J, Butcher B, Calao M, Walsh N, O'Sullivan C, Smith T, Littlejohn G.   +9 more
europepmc   +1 more source

Pharmacophore Modeling of Janus Kinase Inhibitors: Tools for Drug Discovery and Exposition Prediction. [PDF]

Molecules
Fischer F, Temml V, Schuster D.
europepmc   +1 more source

The Use of Janus Kinase Inhibitors for Primary Neutrophilic Cicatricial Alopecias.

Int J Trichology
Balfour AN, Osborne S, Mesinkovska NA.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Janus kinase inhibitors: efficacy and safety

Current Opinion in Rheumatology, 2023
Purpose of review Janus kinase inhibitors (JAKi) have been available for the treatment of rheumatoid arthritis (RA) since 2012 and are indicated for patients with active disease despite csDMARD therapy. Efficacy and safety, as demonstrated in the clinical trials, was similar to biologics. A recent post marketing trial suggested
Stanley, Cohen, Virginia, Reddy
openaire   +2 more sources

Janus kinase inhibitors for alopecia areata

Journal of the American Academy of Dermatology, 2023
Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refractory to treatment. JAK inhibitors have changed that; now, treatment of moderate-to-severe AA is possible. Here, we briefly review the history of and rationale for JAK inhibitor treatment of AA, phase 3 clinical trial data, and ...
Brett A, King, Brittany G, Craiglow
openaire   +2 more sources

Investigational Janus kinase inhibitors

Expert Opinion on Investigational Drugs, 2013
Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.
Constantine S, Tam, Srdan, Verstovsek
openaire   +2 more sources

Oral Janus kinase inhibitors for atopic dermatitis

Annals of Allergy, Asthma & Immunology, 2023
Atopic dermatitis (AD) is one of the most common inflammatory skin conditions. The pathogenesis of AD involves skin barrier disruption and immune activation of T-helper (TH)2 and TH22 and varying degrees of TH1 and TH17 activation in various patient subtypes.
Daniela, Mikhaylov, Benjamin, Ungar, Yael, Renert-Yuval, Emma, Guttman-Yassky   +3 more
openaire   +2 more sources